Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lack of interim OS benefit undermines Roche’s Avastin in glioblastoma

This article was originally published in Scrip

Executive Summary

Interim results show that Roche's Phase III AVAglio trial, investigating Avastin (bevacizumab) used in addition to standard treatment in patients with newly diagnosed glioblastoma multiforme (GBM), has failed to meet its co-primary endpoint of overall survival (OS). This is disappointing news for Roche: its plans to make Avastin the backbone of drug treatment across a variety of cancers depend on physicians and payers perceiving that the drug adds to patient life expectancy, and the latest data does not help that cause.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC019489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel